Arcus in supply deal with AVEO Oncology for casdatifan combo in kidney cancer
Seeking Alpha ·
Arcus Biosciences ( RCUS ) has signed a supply agreement with AVEO Oncology for the latter to supply its kidney cancer drug Fotivda (tivozanib) as part of combination studies with the former's casdatifan. Casdatifan is a small-molecule HIF-2α inhibitor, while Fotivda is a
AI 시장 분석
Acredo BioScience (RCUS) has entered into a supply agreement with AVEO Oncology to conduct a combination clinical trial of a kidney cancer treatment. This collaboration is expected to accelerate the innovative kidney cancer combination research by combining Acredo's Casdote and AVEO's Pritelivant. Investors will closely watch if the combination of the two new drugs will secure competitiveness in the future kidney cancer treatment market.
상승 영향
- Biotech — The acceleration of combination clinical trials of kidney cancer treatments Casdote and Pritelivant increases the chances of success in new drug development and pipeline value.
DYAX 전담 분석
Acredo and AVEO's partnership is a significant step in the development of combination therapies for kidney cancer treatment. The combination of Casdote and Pritelivant has shown promising results in preclinical studies, and this clinical trial will provide valuable data to support their approval. The success of this trial will not only bring new hope to patients with kidney cancer but also showcase the potential of combination therapies in this space.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 67% · Bearish (Short) 33%
435 participants
